Results 1 to 10 of about 39,545 (213)
Renoprotective Effects of DPP-4 Inhibitors
Antioxidants, 2021 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D).
Yuichi Takashi +2 more
exaly +3 more sources
Clinical Use of DPP-4 Inhibitors
Frontiers in Endocrinology, 2019 DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz, Gallwitz Baptist
exaly +3 more sources
Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data [PDF]
BMC MedicineBackground Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen +8 more
doaj +2 more sources
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022 Ashwani Sharma,1 Tarun Virmani,1 Anjali Sharma,2 Vaishnavi Chhabra,1 Girish Kumar,1 Kamla Pathak,3 Abdulsalam Alhalmi4 1School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, 121105, India; 2Freelancer, Pharmacovigilance Expert, Uttar ...
Abdulsalam Alhalmi +2 more
exaly +2 more sources
Correlation between DPP-4 Gene Expression and T-Cell Subset Marker Genes in Chronic Liver Disease Patients in Eastern India: An Observational Study [PDF]
Indian Journal of Endocrinology and MetabolismIntroduction: The role of dipeptidyl peptidase-4 (DPP-4/CD26) in chronic liver disease (CLD) remains incompletely understood, particularly its interaction with immune cells. This study investigates the association between DPP-4 gene expression and T-cell
Bikramjit Barkondaj +7 more
doaj +2 more sources
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2022 Introduction: The studies in animal models of cirrhosis suggest that dipeptidyl peptidase type 4 (DPP-4) enzymes play a crucial role in disease pathogenesis.
Bikramjit Barkondaj +8 more
doaj +1 more source
Kidney & Blood Pressure Research, 2021 Introduction: Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 ...
Takeshi Hasegawa +7 more
doaj +1 more source
Frontiers in Public Health, 2021 Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu +13 more
doaj +1 more source
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
BMC Nephrology, 2020 Background Dipeptidyl peptidase-4 (DPP-4) is a serine protease that inhibits the degradation of glucagon-like peptide 1. DPP-4 inhibitors are used worldwide to treat type 2 diabetes mellitus and were recently shown to have pleiotropic effects such as ...
Ayano Kubo +6 more
doaj +1 more source